The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC CLL 2026 | How has the harmonization of genomic profiling in Sweden impacted patient access to CLL diagnostics?
Richard Rosenquist, MD, PhD, Karolinska Institute, Solna, Sweden, discusses the impact of national harmonization of comprehensive genomic profiling, noting that efforts in Sweden have enabled equal access to diagnostics nationwide, benefiting patients with hematologic malignancies, including chronic lymphocytic leukemia (CLL). This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So in Sweden we started almost 10 years ago to join forces and develop the diagnostic tests in a similar way in order to pave the way for precision medicine. So one of the first efforts were to design gene panels and that is where you select the genes that are of particular interest. And we developed one myeloid gene panel for myeloid malignancies and one panel for lymphoid malignancies...
So in Sweden we started almost 10 years ago to join forces and develop the diagnostic tests in a similar way in order to pave the way for precision medicine. So one of the first efforts were to design gene panels and that is where you select the genes that are of particular interest. And we developed one myeloid gene panel for myeloid malignancies and one panel for lymphoid malignancies. And in this way, it was possible to harmonize how we perform this analysis using the same protocols, the same interpretation, and also the storing of the data afterwards. And I would say that this has helped us to harmonize across the country so individual patients get the same access to the same type of diagnostics independent of where they live. And this includes, of course, hematologic malignancies at large, but also CLL patients. And we do routinely now a gene panel for patients with CLL across the country.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
